RESEARCH



Platelet-rich fibrin vs. buccal advancement flap for closure of oroantral communications: a prospective clinical study

Stefan Hunger^{1,2} · Stefan Krennmair^{1,3} · Gerald Krennmair⁴ · Sven Otto⁵ · Lukas Postl^{1,3} · Danilo-Marc Nadalini²

Received: 6 October 2022 / Accepted: 26 December 2022 / Published online: 6 January 2023 © The Author(s) 2023

Abstract

Objectives The primary aim was to evaluate the success of the defect closure (tight or open) of oroantral communications (OAC) after treatment with platelet-rich fibrin (PRF) clots or a buccal advancement flap (BAF). Secondary outcome measurements were the evaluation of the wound healing, the displacement of the mucogingival border (MGB), and the pain level. **Material and methods** Fifty eligible patients with an OAC defect larger than 3 mm were randomly assigned to either PRF (test group, n=25) or BAF (control group, n=25) for defect closure. In a prospective follow-up program of 21 days, the defect closure healing process, the wound healing course using Landry's wound healing index (score: 0–5), the displacement of the MGB, and the postoperative pain score were evaluated.

Results Five patients in each group were lost to follow-up resulting in 40 patients (20 in each group) for continuous evaluation. On postoperative day 21 (study endpoint), no difference regarding success rate (defined as closure of OAC) was noticed between the test (90%; 18/20) and control group (90%; 18/20). A univariate analysis showed significant differences for age and defect size/height for the use of PRF between successful-tight and open-failed defect healing. At the final evaluation, a significantly (p = 0.005) better wound healing score, a lower displacement of the MGB as well as lower pain-score were seen for the use of PRF.

Conclusions Based on the findings of the current study, the use of platelet-rich fibrin represents a reliable and successful method for closure of oroantral communications. The use of PRF clots for defect filling is associated with lowered pain levels and less displacement of the mucogingival border.

Clinical relevance The defect size should be taken into account when choosing the number and size of PRF plugs.

Keywords Platelet-rich fibrin \cdot Buccal advancement \cdot Closure of oroantral communications \cdot Healing \cdot Mucogingival border \cdot Lukas Postl and Danilo-Marc Nadalini contributed equally to this work.

Lukas Postl Lukasleo@gmx.at

¹ Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria

- ² Clinic of Oral and Maxillofacial Surgery, Kepler University Hospital, Johannes Kepler University, Krankenhausstraße 7a, Linz, Austria
- ³ NumBioLab, Ludwig-Maximilians University of Munich, Munich, Germany
- ⁴ Head of Department of Prosthodontics, Sigmund Freud University Vienna, Freudplatz 1, 1020 Vienna, Austria
- ⁵ Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians-University Munich, Lindwurmstr. 2a, 80337 Munich, Germany

Introduction

Oroantral communications (OAC) are unnatural openings between the oral cavity and the maxillary sinus, which occur due to loss of the soft and/or hard tissue separating these compartments [1]. The most common causes for OAC are tooth extractions in the posterior area of the maxilla, where there is a close topographical relationship between the root apices and the maxillary antrum. OAC may also form following the removal of maxillary cysts, tumors, facial traumata or during dentoalveolar and implant surgery [2–4]. When closure of an OAC fails, the opening may become epithelialized and develop into an oroantral fistula (OAF). This persistent communication between the oral cavity and the maxillary sinus can act as a pathway for bacterial and fungal penetration and has been frequently reported to induce maxillary sinusitis [5, 6].

Numerous treatment strategies have been developed for the management of OAC and OAF and have shown high rates of successful defect closure [7]. To date, the most commonly used method is a surgical approach using a buccal advancement flap (BAF), a technique which was first introduced by Rehrman in 1936 and has become the method of first choice for many clinicians, mainly due to its simplicity, reliability, and versatility [8–11]. Further popular types of local flaps are buccal fat-pad flaps and palatal flaps, but also free mucosal grafts, distant flaps such as tongue flaps, and the use auricular cartilage or bone grafts (e.g., from the chin or retromolar region) have proven to be viable methods for OAC/OAF closure [4]. However, postoperative pain and swelling are potential complications following all surgical options, but a specific drawback of local buccal flaps such as the BAF is vestibular shortening and loss of keratinized gingiva, which may have an impact on future prosthetic rehabilitation [7].

Recently, considerations of alternative treatment methods have included the successful use of plasma-rich fibrin (PRF) for OAC as reported by Demetoglu et al. [12], Assad et al.[13] and Bilginalyar [14]. The clinical outcome of OAC closure using PRF and BAF was compared in a randomized evaluation by Bilginaylar [15], and both methods were proven to be successful. However, postoperative pain and swelling was reduced when PRF was used. Furthermore, there is evidence that PRF has a beneficial effect on wound healing, which makes this method attractive for OAC/OAF closure. Previous studies have shown that wound healing after tooth extraction improved when the extraction socket was filled with PRF [16-19]. Although most case-series and comparative studies have evaluated the results of OAC closure by using clinical assessment only, there is still a lack of information about the detailed course of wound healing, for example by using a defined healing index. Based on several clinical parameters (redness, presence of bleeding, granulation tissue, epithelialization, suppuration), the wound healing index of Landry et al. [20] provides ratings from very poor to excellent healing and allows the evaluation of the wound healing process for comparing the effect of different treatment methods [17–19]. This index has been previously

used in the report by Srinivas et al. [21] for judging the course of the wound healing after treating post-extraction sockets with PRF. Further parameters, which have not yet been evaluated and compared in detail for the use of PRF vs. BAF for OAC closure, are the displacement of the mucogingival border as well as the subjective patient-rated perception of pain and swelling.

As there is a lack of clinical data on OAC defect closure after PRF treatment, this study was conducted and focuses on two major aims: 1) The primary aim is to compare the wound healing outcome of the OAC defect closure with clinical parameters after treatment with PRF clots or after surgical treatment with a BAF. 2) The secondary aim is to assess the patient-related and surgery-related risk factors affecting the healing process and to determine the wound healing course by using a specific wound healing index. In addition, the displacement of the mucogingival line and the patient-scored pain level for both groups are evaluated. The initial working hypothesis is that the use of PRF and the buccal flap will not differ for the final clinical wound healing outcome of OAC defect coverage, but may be different regarding the wound healing course, the displacement of the mucogingival borderline and patient-related postoperative perception.

Material and methods

Study design—patient selection

The study was designed as a single-center, prospective, randomized, controlled follow-up study and was conducted at the author's institution. During the period between December 2019 and July 2020, 50 consecutive patients (Table 1) were included for surgical OAC closure. Depending on the used defect coverage method, the patients were randomly assigned to either the PRF group (test group, n=25) or to the BAF group (control group; n=25). Randomization for the treatment method was performed using a permuted block-randomization approach (block length either 2, 4, or 6) without stratification and allocation to groups was done preoperatively by the sequentially numbered opaque sealed envelope (SNOSE) technique. For

Table 1 Exclusion criteria	Patient-specific	Diabetes with HbA1c>7,5%	
		Use of antirheumatic drugs, antiresorptive medications (such as bisphos- phonates) or corticoids	
	Anatomical-specific and surgery-specific	Oroantral communication due to other reasons (traumatic, neoplastic,)	
		Communications with a diameter < 3 mm	
		Recurrence of a communication (reoperation is necessary)	

creating the randomization list, the R package "blockrand" (blockrand: Randomization for Block Random Clinical Trials, Greg Snow, R package version 1.5) was used. Each patient was given a detailed description of the procedure and signed an informed consent document prior to inclusion in the follow-up program. The study protocol had been approved by the local ethics committee (EC No: 1192/2019) and the study was conducted in accordance with good clinical practices and the Declaration of Helsinki. The study was self-funded by the authors and their institution.

OAC: diagnosis-morphology-location

The diagnosis for OAC was initially assessed by clinical examination using a conventional blunt probe (diameter: 1 mm) and by the patient performing the Valsalva pressure maneuver. The blunt probe was used to carefully palpate the defect in order to detect an OAC. The Valsalva pressure maneuver was additionally performed on each patient and in case of air leakage from the maxillary sinus, an OAC was also assumed. In case of a palpable defect, an apical perforation size of at least 3 mm was assessed using a 3 mm probe. In the further course, the perforation size was verified using detailed radiographic evaluation such as CBCT. The defect area, the mesial and the distal defect length were calculated. The morphology of the OAC was defined in a parallel-walled, root-shaped and inverse-rootshaped (higher apical width) design. Randomization for the treatment method was performed using a permuted block-randomization approach (block length either 2, 4, or 6) without stratification. For creating the randomization list, the R package "blockrand" (blockrand: Randomization for Block Random Clinical Trials, Greg Snow, R package version 1.5) was used.

Surgical approach

According to the randomization protocol, surgical closure of OAC was performed using either platelet-rich fibrin (PRF; test group, n = 25) or the buccal advancement flap (BAF; control group, n = 25). All procedures were performed by the same experienced surgeon (S.H.) under local anesthesia (Xylanest® 2%; Gebro Pharma). Postoperatively, patients in both groups were given amoxicillin (Amoxicillin/Clavulanic Acid 875 mg/125 mg or Clindamycin 600 mg) three times/ day for 7 days and ibuprofen 600 mg (if needed) and were instructed to rinse their mouth (2 weeks/0.12% chlorhexidine gluconate solution/twice daily) and to use a nasal decongestant (Fentrinol®, twice daily for 5 days). They were also advised not to blow their noses for 21 days.

Platelet-rich fibrin (PRF)—test group

According to the protocol of Choukron's [22] PRF production, 4 glass tubes of 10 ml of patient venous blood were centrifuged (1300 revolutions/8 min at 210 G) for clot production. Figure 1 shows a glass tube after centrifugation. Two PRF clots were condensed by stamp pressure and two PRF clots were formed into membranes. PRF clots were inserted into the OAC defect (Fig. 2) and fixed on mucosal margins with absorbable sutures (Vicryl® 4–0) preventing dislocation in the maxillary sinus. Both PRF membranes were placed in two layers over the PRF clots and were also fixed to the marginal gingiva with a Laurell suture (absorbable, Vicryl 4–0).

Buccal advancement flap (BAF)—control group

A trapezoid full mucoperiosteal flap was prepared [8–11] consisting of a crestal incision with a mesial and distal release suitable for flap elevation. For tension-free wound closure, a basal periosteal releasing incision parallel to the coronal margin was performed. Before wound closure an incision removal of the epithelial lining of the oroantral communication was done. The trapezoidal flap, consisting of epithelium, connective tissue and periosteum, was positioned over the defect by means of holding stitches (Vicryl 4/0 DA 0.45 m, Johnson & Johnson, New Brunswick, New Jersey, USA) from the buccal flap to the palatal mucosa. Final adaptation was made with single

Fig. 1 Picture during treatment shows the production of PRF: Centrifugation results in a fibrin clot (PRF) in the center of the tube. Red blood cells collect at the base of the tube and acellular plasma is located at the top layer of the tube (The three areas are indicated by white lines)




Fig. 2 Clinical picture during treatment: an extraction socket in region 26 is shown directly after the placement of a PRF clot



sutures (Vicryl 4/0 DA 0.45 m, Johnson & Johnson, New Brunswick, New Jersey, USA).

Clinical analyses

The patients were regularly and prospectively followed up with recalls on the postoperative days 7 and 21. Additional recall visits were scheduled, if any clinical problems were encountered. All follow-up visits comprised evaluation of the clinical healing outcome such as defect tightness (primary outcome measurement) for the defect closure of oroantral communication using PRF (test group) or buccal advancement flap (BAF; control group). Secondary outcome measurements included -1) evaluation and comparison of patient-related, surgery-related or anatomical risk factors affecting the wound healing process for OAC treated with PRF or BAF, -2) comparison of the wound healing course between PRF and BAF using a scoring system with defined healing indices, -3) evaluation of the displacement of mucogingival line as well as -4) evaluation of postoperative pain and of the use of painkillers.

Primary outcome measurement

The assessment of the primary outcome measurements during the first 21 days included the evaluation of the clinical outcome (tight or open) of the defect closure process for both groups. Figure 3 shows an example from the PFR group, Fig. 4 an example from the BAF group. The tightness of the defect closure was checked by applying a plunger probe (1 mm diameter at the apex) with gentle pressure against the newly formed tissue on postoperative day 7 and day 21. Tightness of the defect closure was also assessed using a dichotomous score (yes = 1; no = 0) and was compared between both groups.

Secondary outcome measurements

- 1. Patient-related and surgical-anatomical risk factors were evaluated and compared for the presence of successful (tight) defect closure or open defect (failed-healed) OAC for the study endpoint (evaluation at day 21).
- 2. Clinical wound healing: Using the wound healing index of Landry et al., the course of wound healing of OAC closure was assessed on day 7 and day 21 in the PRF and




Fig. 3 Patient of the PRF group with an OAC in region 27 (left side: postoperatively, center: 1 week post op, right side: 3 weeks post op)



Fig. 4 Patient of the BAF group with an OAC in region 16 (left side: postoperatively, center: 1 week post op, right side: 3 weeks post op)

BAF group. Two independent assessors (M.M.; G.F.) not involved in the surgical procedure rated the following five items dichotomously (0/1) resulting in a summarized score ranging from 0 (worst) to 5 (highest).

- 3. color of the surrounding mucosa: inflammatory red (score: 0) / healthy pink (score: 1).
- 4. bleeding on palpation: presence = 0 / absence = 1
- 5. granulation tissue: presence = 0 / absence = 1
- incision margin/re-epithelialization: presence = 0 / absence = 1
- 7. suppuration: presence = 0 / absence = 1

-3) Offset of the mucogingival line: The mucogingival borderline was initially measured from the jaw ridge center to the mucogingival borderline in millimeters using a periodontal probe. Measurements of the distance were done preoperatively (baseline) and on postoperative days 7 and 21 and were compared within the groups as well as between the PRF and BAF group.

-4) Postoperative pain/use of painkillers. All patients received a pain protocol for assessing pain level and the pain

medications taken daily for the first seven days. Pain level was assessed with a visual analog scale ranging from 0 (= no pain) to 10 (= severe pain). Pain level was followed up for 7 days and was compared between the test group and the control group. In addition, the number of painkillers used was also assessed for 7 days and evaluated for both groups.

Statistical analysis

All statistical tests and confidence intervals were used in an explorative way, therefore no correction of the type I error (two-sided, 5%) was made except for post-hoc comparisons. All results are therefore descriptive. For all statistical analyses, the open-source statistical computing software R Version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org) was used.

Fisher's exact test $(2 \times 2 \text{ tables})$ or the exact Chi-Square test (n x k tables) were used for unpaired categorical variables. In the case of two independent groups of ordinal variables the exact Mann–Whitney U test was used. As normal-distribution-test for continuous variables, the Kolmogorov-Smirnov-Test with Lilliefors Correction at a type-I error-rate of 10% was used. As test of variance homogeneity for continuous variables, the Levene-Test was used at a type-I error-rate of 5%. In the case of two independent groups the unpaired two sample t-test respectively Welch's two sample *t*-test in case of variance heterogeneity was used. In case of not normally distributed data the exact Mann-Whitney U test was used. For paired normally distributed data (verification with Kolmogorov-Smirnov-Test with Lilliefors Correction at a type-I error-rate of 10%) the paired t-test was used. If the paired data was not normally distributed the exact Wilcoxon test was used. In case of more than 2 repeated measurements repeated ANOVA (post hoc comparisons using Bonferroni-adjusted paired t-tests) for normally distributed data or Friedman's rank analysis of variance (post hoc comparisons using the Schaich-Hamerle approach) for not normally distributed data was used.

For assessing the equivalence regarding the outcome "defect closure after 21 days," an exact two-sided 90% confidence interval for the difference of the proportion of defect closure with an equivalence region of $\pm 20\%$ was used. The relationship between a metric variable and dichotomous variable was estimated by the point biserial Bravais-Pearson-correlation-coefficient or by the point biserial Spearman-correlation-coefficient (in case of no normal distribution). As test for the correlation coefficient against the reference value zero (no correlation), a test based on the t-distribution was used.

Results

Patients

Out of the 50 patients originally included (n = 50), five patients in the test group (5/25; 20%) and five patients in the control group (5/25; 20%) were lost to follow-up due to lack of compliance with continuous evaluation. In detail, 3 patients were lost on day 7 (3×control group; BAF) and 7 patients (5 in test group [PRF], 2 in control group [BAF]) were lost on day 21 resulting in 10 patients (5 in each group) without continuous follow-up. The reasons for the drop-out varied and primarily involved the extramural follow-up setting. Finally, 20 patients in the test group and 20 patients in the control group could be continually followed on the postoperative days 7 and 21 (final endpoint evaluation) and thus contributed to the evaluation of primary and secondary outcome measurements. Table 2 shows the patient characteristics such as age, gender, body mass index along with the *p*-values indicating that there were no significant differences between the test and control group for each parameter. Defect area and defect morphology of test and control group are shown in Table 3.

 Table 2
 Patient
 characteristics
 of all patients.
 Data are given as

 $mean \pm standard$ deviation or absolute/relative frequencies

	PRF (<i>n</i> =25)	BAF (<i>n</i> =25)	<i>p</i> -value
Patient-rela	ted		
age	47.0 ± 14.9	51.6 ± 10.9	0.226
sex (f/m)	11(44%)/14(56%)	12(48%)/13(52%)	> 0.999
BMI	26.9 ± 4.9	24.7 ± 4.6	0.066
Smoking	7(28%)	9(36%)	0.762

Table 3 Defect area and morphology. Data are given as mean \pm standard deviation or absolute/relative frequencies

	$\begin{array}{c} \text{PRF} \\ (n = 20) \end{array}$	BAF (<i>n</i> =20)	<i>p</i> -value
Anatomical site related			
localisation first premolar	0(0%)	0(0%)	> 0.999
localisation second premolar	1(5%)	1(5%)	> 0.999
localisation first molar	10(50%)	11(55%)	> 0.999
localisation second molar	6(30%)	3(15%)	0.451
localisation wisdom tooth	3(15%)	5(25%)	0.695
defect size in mm ²	40.5 ± 33.1	54.6 ± 32.6	0.108
mesial bone height in mm	7.5 ± 2.4	5.0 ± 3.3	0.008
distal bone height in mm	6.4 ± 2.4	4.8 ± 2.9	0.065


Primary outcome—defect closure

The day-7 follow-up evaluation of the defect closure of the oroantral communication showed a success rate of 95% (19/20) for the PRF group and 95% (19/20) for the BAF group. Evaluation on postoperative day 21 (study endpoint) revealed a success rate of 90% (18/ 20) for both the test and the control group. Figure 3 shows an example from the PFR group, Fig. 4 an example from the BAF group. Figure 5 presents information about successful defect closure including exact 95% confidence intervals. Considering the hypothesized absence of any difference between the two groups regarding successful defect closure, a statistically relevant equivalence of both groups (p=0.043; 90% CI: -19.69-+19.69%) based on an equivalence region of 20% was found.

Secondary outcomes

Patient-related and surgical risk factors

Table 4 shows the univariate risk factor analysis for patientrelated and surgical/anatomical risk factors for the use of PRF or BAF with tight-successful or open-failed conditions of OAC closure at the time of the endpoint evaluation



Successful Defect Closure

Fig. 5 Success of defect closure

(day 21). There were significant differences for age, defect size/height for the use of PRF between successful-tight and open-failed defect healing. In addition, a moderate positive correlation (r=0.491) between defect size and occurrence of a persistent oroantral connection was found in the PRF group after 21 days (p=0.028). In contrast, at the endpoint evaluation (at day 21) no significant differences between successful and failed healing outcome were found for the risk factors when BAF was used.

Wound healing according Landry index

The results for the clinical healing course in the test and the control group on day 7 and day 21, which were evaluated using the Landry wound healing index, are shown in Fig. 6.

For both groups (PRF and BAF) a significant increase (p < 0.001) of healing was noticed between day 7 and day

21. Initially, at day 7 a better healing score was observed for the use of BAF (2.5 ± 0.8) than for PRF (2.1 ± 0.3) . However, on day 21 an inverse healing course was seen showing a significantly (p=0.005) better wound healing score for the use of PRF (4.5 ± 0.8) than for the use of BAF (3.7 ± 0.9) .

Displacement of MGL

Clinical displacement of the mucogingival line in the PRF and the BAF group at baseline (preoperatively), on day 7 and day 21 is shown in Table 5. Regarding the values related to the mucogingival line, there was a significant overall difference (p < 0.001) in the BAF group, which was caused by significantly lower values on day 7 (p < 0.001) and day 21 (p < 0.001) compared to baseline. For the PRF group no post-hoc significances were observed.

Table 4Univariate risk factoranalysis for patient-related andsurgery-related/anatomicalrisk factors for using PRFor BAF. Data are given asmean ± standard deviation orabsolute/relative frequencies

		PRF day 21			BAF day 21	
	OAC-closed	OAC -open	p-value	OAC-closed	OAC -open	<i>p</i> -value
	n = 18	n=2		n = 18	n=2	
Sex			0.479			0.189
f	9 (50.0%)	0 (0.0%)		7 (38.9%)	2 (100%)	
m	9 (50.0%)	2 (100%)		11 (61.1%)	0 (0.0%)	
Age	46.2 ± 15.1	68.0 ± 5.7	0.037	50.8 ± 10.6	60.5 ± 6.4	0.258
BMI	26.91 ± 5.3	30.1 ± 5.4	0.442	25.4 ± 5.1	20.5 ± 1.1	0.095
Area	32.41 ± 16.8	113.1 ± 66.2	0.021	51.7 ± 33.1	80.4 ± 1.0	0.379
mesial bone height	8.0 ± 1.9	2.9 ± 0.04	0.011	5.2 ± 3.3	3.4 ± 3.2	0.442
distal bone height	6.8 ± 2.1	3.1 ± 2.9	0.126	4.8 ± 2.9	4.8 ± 4.9	0.937
Side			0.495			> 0.999
right	10 (55.6%)	2 (100%)		11 (61.1%)	1(50.0%)	
left	8 (44.4%)	0 (0.0%)		7 (38.9%)	1(50.0%)	
Location						
First premolars	0(0.0%)	0(0.0%)	> 0.999	0 (0.0%)	0 (0.0%)	> 0.999
Second premolars	1(5.6%)	0(0.0%)	> 0.999	1 (5.6%)	0 (0.0%)	> 0.999
First molars	9(50.0%)	1(50.0%)	> 0.999	9 (50.0%)	2 (100%)	0.479
Second molars	5(27.8%)	1(50.0%)	0.521	3 (16.7%)	0 (0.0%)	> 0.999
Wisdom teeth	3(16.7%)	0(0.0%)	> 0.999	5 (27.8%)	0 (0.0%)	> 0.999
Morphology			0.132			0.479
Parallel	5 (27.8%)	0 (0.0%)		4 (22.2%)	0 (0.0%)	
Root-shaped	9 (50.0%)	0 (0.0%)		5 (27.8%)	0 (0.0%)	
Inverse-root	4 (22.2%)	2 (100%)		9 (50.0%)	2 (100%)	
Smoker			> 0.999			> 0.999
No	13 (72.2%)	1 (50.0%)		12 (66.7%)	1 (50.0%)	
Yes	5 (27.8%)	1 (50.0%)		6 (33.3%)	1 (50.0%)	
Closing attempts			0.016			0.195
First closing attempt	17 (94.4%)	0 (0.0%)		17 (94.4%)	1 (50.0%)	
Revision	1 (5.6%)	2 (100%)		1 (5.6%)	1 (50.0%)	


Postoperative discomfort

Postoperative pain and number of painkillers used per day are presented in Figs. 7 and 8. Pain levels and the number of painkiller medications needed were significantly higher (p < 0.001) in the BAF group compared to the group with PRF.

Discussion

The findings of the present study confirm the initial hypothesis that there are no differences between surgical treatment with a buccal advancement flap and the treatment with platelet-rich fibrin clots/membranes regarding the clinical success rates for the closure of oroantral communication. The final evaluation at the study endpoint on day 21 showed a closure success rate of 90% for both methods demonstrating that the use of platelet rich fibrin (PRF) may be a promising alternative approach for OAC closure.

However, there is inconsistent data about the recommended number and form of PRF clots. The findings of the present study as well as the results of the previous studies by Bilginaylar, Gülsen and Agarwal have indicated high success rates, although a different number of clots was used in each study [15, 23, 24]. In the study by Bilginaylar et al., two platelet-rich fibrin clots were pressed into plugs and placed in the extraction socket for OAC closure [15], whereas Gülsen et al. used six clots for this purpose [23]. Nevertheless, both studies reported a successful healing process. In the study by Agarwal et al. a slightly different protocol is described, where four clots were produced in total, but only three of those were pressed into a cylinder-shaped plug to seal the opening, while the remaining clot was shaped into a membrane which was subsequently folded under the buccal and palatinal mucoperiostal flap for separating the clot from the oral cavity [24]. A similar technique was also used in this present study but instead of three clots only two were used for creating the plug and the other two were used for forming the membrane. However, none of the available studies



Healing-Index

Fig. 6 Clinical healing course for the test and the control group on day 7 and day 21 evaluated using the Landry wound healing index

	PRF (n=20)	BAF (n=20)	<i>p</i> -value
MGL: preoperatively	9.1 ± 2.4	8.3 ± 2.4	0.301
MGL: at day 7	9.1 ± 2.4	2.1 ± 2.3	< 0.001
MGL: at day 21	8.9 ± 2.3	1.8 ± 2.1	< 0.001


Table 5 Clinical displacement of the mucogingival line (MGL). Dataare given as mean \pm standard deviation


mentioned above clearly state which number of PRF clots is necessary for achieving successful OAC closure.

Interestingly, the findings of the univariate analysis evaluating the risk factors affecting the defect healing outcome revealed differences between the use of PRF or the buccal advancement flap. For the use of the buccal advancement flap, the patient-related and surgery-related/anatomical risk factors did not differ between successful and failed wound healing outcome. Hence, the failed wound healing observed with a buccal advancement flap may be preferably attributed to patient compliance (nose breathing) and/or surgery-related reasons such as extensive flap tension. In contrast, for the PRF group, the univariate analysis showed significant differences for risk factors such as patient age and defect dimension. In detail, a significant difference between the defect size and success of defect closure was found, suggesting that clinical wound closure may be influenced by the number of plateletrich fibrin clots used, considering that all patients received the same amount of PRF clots. Consequently, an individualized number of clots depending on the defect size might be the key to an improved outcome for oroantral communication defect closure. This will have to be evaluated in future studies.

Furthermore, the univariate risk factor analysis revealed that patient age seems to be a risk factor for a failed or successful outcome when using PRF. This is consistent with the findings of the studies by Miron et al. (2019) and Mamajiwala et al. which demonstrated that platelet-rich fibrin shows age-related differences regarding the protein content. Specifically, PRF from younger patients exhibits a higher platelet concentration, antimicrobial activity, and a denser fibrin network [25, 26]. Moreover, Yajamanya et al. also found that the fibrous protein in PRF changed with age when density decreased and it became increasingly loose; the number of platelets and white blood cells also decreased [27]. Therefore, structural abnormalities of the PRF in the older age group may have to be compensated when working with this method, for example by using a higher number of clots/plugs, by modifying the centrifugation protocol or by selecting alterative treatment procedures.

Fig. 7 Postoperative pain








Fig. 8 Number of painkillers used per day

The results of the systematic review of Miron et al. evaluating 31 clinical studies highlight the positive effects of PRF on wound healing after regenerative treatment of various soft tissue defects in medicine and dentistry [28]. Platelet-rich fibrin has been described as a natural matrix consisting of various wound healing cell types as well as of proteins and various cytokines, which provide functional and structural support for the regeneration process. Apart from several molecules such as collagen, heparan sulfate, elastin and proteoglycans, some plasma-derived proteins such as fibrin, fibronectin, and thrombospondin are transformed into soft tissue at the surface as well into bone in the residual sockets [29–35]. Although the use of PRF has been reported with excellent clinical outcome, no detailed information is available regarding the wound healing course. The findings of the present study using the wound healing score indices of Landry et al. [20] demonstrate that platelet-rich fibrin and the buccal advancement flap have opposite wound healing courses. Initially, the wound healing was significantly better for the end-to-end anastomosed buccal flap compared to the granulation process of platelet-rich fibrin membrane/plug covering the OAC defects. However, at the endpoint evaluation, the healing effect of the platelet-rich fibrin had caught up with the direct flap adaptation and even showed significantly better final clinical wound healing results. This may be attributed to the fact that wound healing with PRF generally takes longer than the direct adaptation of the wound margins with the buccal flap procedures. The fact that the ultimate score rating was higher with the use of the PRF may possibly be explained by the fact that the fibrin/fibronectin clots and membranes had been transformed into soft tissue that showed similar characteristics as the neighboring areas.

Regarding the evaluation of the secondary outcome measurements, the displacement of the mucogingival borderline also showed a significant difference between the two methods. The displacement of the mucogingival borderline after the buccal advancement flap procedure was to be expected, however, there was also a slight displacement of the mucogingival borderline in the platelet-rich fibrin group. This may be attributed to the remodeling process as a result of bundle bone resorption of the extraction sockets. While the extensive displacement of the mucogingival borderline with the buccal advancement flap occurs due to iatrogenic/surgically induced reasons, the comparatively small shift in the PRF group is based on the physiological remodeling processes.

The findings of this present study also confirm the hypothesis that the presence of pain and the use of painkillers needed was significantly different between the two groups. This is consistent with the findings of Bilginaylar et al. and may either be attributed to the less invasive treatment protocol or to the anti-inflammatory activity and immune regulation effects of the platelet-rich fibrin content [15]. Pain reduction was also reported in separate clinical studies of Choukroun et al. and Kumar et al. in which the platelet-rich fibrin was used as a filling material in extraction sockets [36, 37]. It is also known from other areas of oral surgery that PRF can lead to pain reduction [38–41]. A limitation of this study is that it only provides a comparison between two methods of closure of oroantral communications. As previously mentioned in the introduction, there are other methods such as other local flaps, distant flaps, bone grafts as well as leucocyte and platelet rich fibrin. The widely used and well-established buccal advancement flap was chosen in this study to venture a comparison to PRF, but future studies should consider comparing additional methods as well.

Conclusions

According to the findings of the current study, the use of platelet-rich fibrin represents a reliable and successful method for closure of oroantral communications. The use of PRF clots for defect filling is associated with low/ lowered pain levels, a promising healing pattern and a good clinical soft tissue outcome showing similar tissue characteristics as the adjacent region. However, the defect size and hence the number and size of PRF plugs used is decisive for a successful healing outcome. Acknowledgements Thanks to Thomas Forstner from the Department of Applied Systems Research and Statistics, Johannes Kepler University, Altenberger Straße 69, 4040 Linz, Austria for his statistical support. The authors would like to thank Sabina Noreen Würsching for kindly helping us to improve the language of this manuscript.

Author contribution SH, GK, LP and D-MN designed the study. SH, GK and LP wrote the manuscript. All authors were involved in the data collection, the evaluation and revision of the manuscript. All authors read and approved the final manuscript.

Funding Open access funding provided by Johannes Kepler University Linz. This research did not receive any specific grant from funding agencies in the public, commercial, or non-profit sectors, but was supported by Johannes Kepler Open Access Publishing Fund.

Data availability Not applicable.

Declarations

Ethics approval Ethical approval was obtained from the local ethics committee for this study.

Consent for publication All the authors gave consent for the publication.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Bennett RJ, Moore JR (1954) An investigation into the pathology and treatment of oro-antral fistulae of dental origin. J Laryngol Otol 68(8):535–549
- Logan RM, Coates EA (2003) Non-surgical management of an oro-antral fistula in a patient with HIV infection. Aust Dent J 48(4):255–258
- Nezafati S, Vafaii A, Ghojazadeh M (2012) Comparison of pedicled buccal fat pad flap with buccal flap for closure of oro-antral communication. Int J Oral Maxillofac Surg 41(5):624–628
- Parvini P, Obreja K, Sader R, Becker J, Schwarz F, Salti L (2018) Surgical options in oroantral fistula management: a narrative review. Int J Implant Dent 4(1):40
- Borgonovo AE, Berardinelli FV, Favale M, Maiorana C (2012) Surgical options in oroantral fistula treatment. Open Dent J 6:94–98
- Watzak G, Tepper G, Zechner W, Monov G, Busenlechner D, Watzek G (2005) Bony press-fit closure of oro-antral fistulas: a technique for pre-sinus lift repair and secondary closure. J Oral Maxillofac Surg 63(9):1288–1294

- Dergin G, Emes Y, Delilbasi C, Gurler G (2016) Management of the Oroantral Fistula. A Textbook of Advanced Oral and Maxillofacial Surgery 3(2016):3367
- Falci SG, dos Santos CR (2015) Modification of the Vestibular Mucoperiosteal Flap Technique for Closure of Oroantral Fistula. J Craniofac Surg 26(7):e659
- 9. Killey HC, Kay LW (1972) Observations based on the surgical closure of 362 oro-antral fistulas. Int Surg 57(7):545–549
- Lin PT, Bukachevsky R, Blake M (1991) Management of odontogenic sinusitis with persistent oro-antral fistula. Ear Nose Throat J 70(8):488–490
- 11. Rehrmann A (1936) Eine methode zur schliessung von kieferhöhlenperforationen. Dtsch Zahnärztl Wschr 39:1136–1138
- Demetoglu U, Ocak H, Bilge S (2018) Closure of Oroantral Communication With Plasma-Rich Fibrin Membrane. J Craniofac Surg 29(4):e367–e370
- Assad M, Bitar W, Alhajj MN (2017) Closure of Oroantral Communication Using Platelet-rich Fibrin: A Report of Two Cases. Ann Maxillofac Surg 7(1):117–119
- Bilginaylar K (2018) The Use of Platelet-Rich Fibrin for Immediate Closure of Acute Oroantral Communications: An Alternative Approach. J Oral Maxillofac Surg 76(2):278–286
- Bilginaylar K (2019) Comparison of the Clinical Outcomes of Buccal Advancement Flap Versus Platelet-Rich Fibrin Application for the Immediate Closure of Acute Oroantral Communications. J Craniofac Surg 30(1):e45–e49
- Hauser F, Gaydarov N, Badoud I, Vazquez L, Bernard JP, Ammann P (2013) Clinical and histological evaluation of postextraction platelet-rich fibrin socket filling: a prospective randomized controlled study. Implant Dent 22(3):295–303
- 17. Blinstein B, Bojarskas S (2018) Efficacy of autologous platelet rich fibrin in bone augmentation and bone regeneration at extraction socket. Stomatologija 20(4):111–118
- Areewong K, Chantaramungkorn M, Khongkhunthian P (2019) Platelet-rich fibrin to preserve alveolar bone sockets following tooth extraction: A randomized controlled trial. Clin Implant Dent Relat Res 21(6):1156–1163
- Al-Maawi S, Becker K, Schwarz F, Sader R, Ghanaati S (2021) Efficacy of platelet-rich fibrin in promoting the healing of extraction sockets: a systematic review. Int J Implant Dent 7(1):117
- Landry RG (1985) Effectiveness of benzydamine HC1 in the treatment of periodontal post-surgical patients: Faculty of Dentistry, University of Toronto
- Srinivas B, Das P, Rana MM, Qureshi AQ, Vaidya KC, Ahmed Raziuddin SJ (2018) Wound Healing and Bone Regeneration in Postextraction Sockets with and without Platelet-rich Fibrin. Ann Maxillofac Surg 8(1):28–34
- 22. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J et al (2006) Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101(3):e37-44
- Gülşen U, Şentürk MF, Mehdiyev İ (2016) Flap-free treatment of an oroantral communication with platelet-rich fibrin. Br J Oral Maxillofac Surg 54(6):702–703
- Agarwal B, Pandey S, Roychoudhury A (2016) New technique for closure of an oroantral fistula using platelet-rich fibrin. Br J Oral Maxillofac Surg 54(2):e31–e32
- 25. Miron RJ, Dham A, Dham U, Zhang Y, Pikos MA, Sculean A (2019) The effect of age, gender, and time between blood draw and start of centrifugation on the size outcomes of platelet-rich fibrin (PRF) membranes. Clin Oral Investig 23(5):2179–2185
- 26. Mamajiwala AS, Sethi KS, Raut CP, Karde PA, Mangle NM (2020) Impact of different platelet-rich fibrin (PRF) procurement methods on the platelet count, antimicrobial efficacy, and fibrin network pattern in different age groups: an in vitro study. Clin Oral Investig 24(5):1663–1675

- 27. Yajamanya SR, Chatterjee A, Babu CN, Karunanithi D (2016) Fibrin network pattern changes of platelet-rich fibrin in young versus old age group of individuals: A cell block cytology study. J Indian Soc Periodontol 20(2):151
- Miron RJ, Fujioka-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Choukroun J (2017) Platelet-rich fibrin and soft tissue wound healing: a systematic review. Tissue Eng Part B Rev 23(1):83–99
- Kobayashi E, Flückiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B et al (2016) Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig 20(9):2353–2360
- 30. Miron RJ, Moraschini V, Fujioka-Kobayashi M, Zhang Y, Kawase T, Cosgarea R et al (2021) Use of platelet-rich fibrin for the treatment of periodontal intrabony defects: a systematic review and meta-analysis. Clin Oral Investig 25(5):2461–2478
- Miron RJ, Moraschini V, Del Fabbro M, Piattelli A, Fujioka-Kobayashi M, Zhang Y et al (2020) Use of platelet-rich fibrin for the treatment of gingival recessions: a systematic review and meta-analysis. Clin Oral Investig 24(8):2543–2557
- 32. Fujioka-Kobayashi M, Katagiri H, Kono M, Schaller B, Zhang Y, Sculean A et al (2020) Improved growth factor delivery and cellular activity using concentrated platelet-rich fibrin (C-PRF) when compared with traditional injectable (i-PRF) protocols. Clin Oral Investig 24(12):4373–4383
- 33. Fujioka-Kobayashi M, Schaller B, Mourão C, Zhang Y, Sculean A, Miron RJ (2021) Biological characterization of an injectable platelet-rich fibrin mixture consisting of autologous albumin gel and liquid platelet-rich fibrin (Alb-PRF). Platelets 32(1):74–81
- Miron RJ, Chai J, Zheng S, Feng M, Sculean A, Zhang Y (2019) A novel method for evaluating and quantifying cell types in platelet rich fibrin and an introduction to horizontal centrifugation. J Biomed Mater Res, Part A 107(10):2257–2271
- Eren G, Kantarcı A, Sculean A, Atilla G (2016) Vascularization after treatment of gingival recession defects with platelet-rich fibrin or connective tissue graft. Clin Oral Investig 20(8):2045–2053
- Choukroun J, Diss A, Simonpieri A, Girard M-O, Schoeffler C, Dohan SL et al (2006) Platelet-rich fibrin (PRF): a second-generation platelet concentrate Part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 101(3):e56–e60
- Kumar YR, Mohanty S, Verma M, Kaur RR, Bhatia P, Kumar VR et al (2016) Platelet-rich fibrin: the benefits. Br J Oral Maxillofac Surg 54(1):57–61
- Lektemur Alpan A, Torumtay CG (2020) PRF improves wound healing and postoperative discomfort after harvesting subepithelial connective tissue graft from palate: a randomized controlled trial. Clin Oral Investig 24(1):425–436
- 39. Meza-Mauricio J, Furquim CP, Geldres A, Mendoza-Azpur G, Retamal-Valdes B, Moraschini V et al (2021) Is the use of plateletrich fibrin effective in the healing, control of pain, and postoperative bleeding in the palatal area after free gingival graft harvesting? A systematic review of randomized clinical studies. Clin Oral Investig 25(7):4239–4249
- 40. Soto-Peñaloza D, Peñarrocha-Diago M, Cervera-Ballester J, Peñarrocha-Diago M, Tarazona-Alvarez B, Peñarrocha-Oltra D (2020) Pain and quality of life after endodontic surgery with or without advanced platelet-rich fibrin membrane application: a randomized clinical trial. Clin Oral Investig 24(5):1727–1738
- Bahammam MA (2018) Effect of platelet-rich fibrin palatal bandage on pain scores and wound healing after free gingival graft: a randomized controlled clinical trial. Clin Oral Investig 22(9):3179–3188

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.